74 related articles for article (PubMed ID: 18483204)
1. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies.
Zheng TS; Burkly LC
J Leukoc Biol; 2008 Aug; 84(2):338-47. PubMed ID: 18483204
[TBL] [Abstract][Full Text] [Related]
2. Cordyceps sinensis extract protects against acute kidney injury by inhibiting perforin expression in NK cells via the STING/IRF3 pathway.
Li S; Pang W; Wang Y; Zhang Y
Aging (Albany NY); 2024 Mar; 16(7):5887-5904. PubMed ID: 38517396
[TBL] [Abstract][Full Text] [Related]
3. Fn14 promotes myoblast fusion during regenerative myogenesis.
Tomaz da Silva M; Joshi AS; Castillo MB; Koike TE; Roy A; Gunaratne PH; Kumar A
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37813488
[TBL] [Abstract][Full Text] [Related]
4. Targeted ablation of Fn14 receptor improves exercise capacity and inhibits neurogenic muscle atrophy.
Tomaz da Silva M; Joshi AS; Koike TE; Roy A; Mathukumalli K; Sopariwala DH; Narkar VA; Kumar A
FASEB J; 2022 Dec; 36(12):e22666. PubMed ID: 36412933
[TBL] [Abstract][Full Text] [Related]
5. Baseline interleukin-10, CD163, and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12-week follow-up study.
Yilmaz M; Demir E; Gürsoy M; Firatli E; Gürsoy UK
J Periodontol; 2023 Jan; 94(1):141-154. PubMed ID: 35819128
[TBL] [Abstract][Full Text] [Related]
6. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges.
Méndez-Barbero N; Gutiérrez-Muñoz C; Blázquez-Serra R; Martín-Ventura JL; Blanco-Colio LM
Cells; 2020 Feb; 9(2):. PubMed ID: 32053869
[TBL] [Abstract][Full Text] [Related]
7. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
[TBL] [Abstract][Full Text] [Related]
8. TWEAK/Fn14 Activation Participates in Skin Inflammation.
Liu Q; Xiao S; Xia Y
Mediators Inflamm; 2017; 2017():6746870. PubMed ID: 29038621
[TBL] [Abstract][Full Text] [Related]
9. TWEAK-binding autoantibodies are generated during psoriatic arthritis and are not influenced by anti-TNF therapy.
Guis S; Berbis P; Stephan D; Bertin D; Amatore F; Balandraud N; Lesavre N; Desplat-Jégo S
J Transl Med; 2016 Jun; 14(1):185. PubMed ID: 27338143
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease.
Sharif MN; Campanholle G; Nagiec EE; Wang J; Syed J; O'Neil SP; Zhan Y; Brenneman K; Homer B; Neubert H; Karim R; Pullen N; Evans SM; Fleming M; Chockalingam P; Lin LL
PLoS One; 2016; 11(5):e0155368. PubMed ID: 27171494
[TBL] [Abstract][Full Text] [Related]
11. TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus.
Doerner JL; Wen J; Xia Y; Paz KB; Schairer D; Wu L; Chalmers SA; Izmirly P; Michaelson JS; Burkly LC; Friedman AJ; Putterman C
J Invest Dermatol; 2015 Aug; 135(8):1986-1995. PubMed ID: 25826425
[TBL] [Abstract][Full Text] [Related]
12. DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy.
Tajrishi MM; Shin J; Hetman M; Kumar A
J Biol Chem; 2014 Jul; 289(29):19985-99. PubMed ID: 24895120
[TBL] [Abstract][Full Text] [Related]
13. TWEAK/Fn14 Signaling Axis Mediates Skeletal Muscle Atrophy and Metabolic Dysfunction.
Sato S; Ogura Y; Kumar A
Front Immunol; 2014; 5():18. PubMed ID: 24478779
[TBL] [Abstract][Full Text] [Related]
14. The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease.
Tajrishi MM; Zheng TS; Burkly LC; Kumar A
Cytokine Growth Factor Rev; 2014 Apr; 25(2):215-25. PubMed ID: 24444596
[TBL] [Abstract][Full Text] [Related]
15. Regulatory circuitry of TWEAK-Fn14 system and PGC-1α in skeletal muscle atrophy program.
Hindi SM; Mishra V; Bhatnagar S; Tajrishi MM; Ogura Y; Yan Z; Burkly LC; Zheng TS; Kumar A
FASEB J; 2014 Mar; 28(3):1398-411. PubMed ID: 24327607
[TBL] [Abstract][Full Text] [Related]
16. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.
Dhruv H; Loftus JC; Narang P; Petit JL; Fameree M; Burton J; Tchegho G; Chow D; Yin H; Al-Abed Y; Berens ME; Tran NL; Meurice N
J Biol Chem; 2013 Nov; 288(45):32261-32276. PubMed ID: 24056367
[TBL] [Abstract][Full Text] [Related]
17. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K
Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
[TBL] [Abstract][Full Text] [Related]
18. TWEAK and TRAF6 regulate skeletal muscle atrophy.
Kumar A; Bhatnagar S; Paul PK
Curr Opin Clin Nutr Metab Care; 2012 May; 15(3):233-9. PubMed ID: 22366923
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-like weak inducer of apoptosis and its potential roles in lupus nephritis.
Liu ZC; Zhou QL
Inflamm Res; 2012 Apr; 61(4):277-84. PubMed ID: 22297307
[TBL] [Abstract][Full Text] [Related]
20. One dose of cyclosporine A is protective at initiation of folic acid-induced acute kidney injury in mice.
Wen X; Peng Z; Li Y; Wang H; Bishop JV; Chedwick LR; Singbartl K; Kellum JA
Nephrol Dial Transplant; 2012 Aug; 27(8):3100-9. PubMed ID: 22294776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
